ImmuPharma plc (AIM:IMM)
London
· Delayed Price · Currency is GBP · Price in GBX 4.200
-0.378 (-8.25%)
Apr 28, 2026, 4:35 PM GMT
ImmuPharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
26.20M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SkinBioTherapeutics | 4.64M |
| Arecor Therapeutics | 1.71M |
| Aptamer Group | 1.38M |
| Fusion Antibodies | 1.60M |
| IXICO | 6.53M |
| hVIVO | 49.66M |
| Ondine Biomedical | 1.18M |
ImmuPharma News
- 5 weeks ago - ImmuPharma Transcript: Investor update - Transcripts
- 6 weeks ago - AIM Market Roundup: Tern, T42 IoT, Atlantic Lithium - The Armchair Trader
- 2 months ago - AIM Market Roundup: Immupharma, Pebble Beach, Tungsten West - The Armchair Trader
- 5 months ago - FTSE Flat as Wall Street Gains Fail to Inspire - Investomania
- 5 months ago - AIM Market Roundup: Trellus Health, Great Western Mining, EMV Capital - The Armchair Trader
- 8 months ago - AIM Market Roundup: ImmuPharma, Rockfire Resources, Likewise - The Armchair Trader
- 8 months ago - AIM Market Roundup: Dewhurst, Metir, Tertiary Minerals - The Armchair Trader
- 8 months ago - AIM Market Roundup: ImmuPharma, N4 Pharma, Versarien - The Armchair Trader